https://www.reuters.com/business/healthcare-pharmaceuticals/mesoblast-soars-us-fdas-nod-review-lead-drug-candidate-2023-03-08/#:~:text=The%20brokerage%20said%20it%20expects,%241.140%20earlier%20in%20the%20session.
Brokerage Jefferies said it expects "significant" U.S. sales of the drug (nah, therapy) in fiscal 2024.
PS: I will be adding on any pull backs.
This post is not to be construed as investment advice because it is not meant to be.
- Forums
- ASX - By Stock
- MSB
- Significant sales in fiscal 2024
Significant sales in fiscal 2024
-
-
- There are more pages in this discussion • 68 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
CC9
Chariot Corporation (ASX:CC9) refines Black Mountain strategy, launching Pilot Mine to seize U.S. lithium opportunity
LU7
Discover the strong preliminary feasibility of the Bécancour Lithium Refinery, showcasing resilience in a low pricing environment and a strategic plan to capitalize on future price recoveries
Add MSB (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.49 |
Change
0.140(10.4%) |
Mkt cap ! $1.701B |
Open | High | Low | Value | Volume |
$1.37 | $1.54 | $1.37 | $23.10M | 15.82M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 24758 | $1.49 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.49 | 73626 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 10033 | 1.485 |
4 | 53700 | 1.480 |
1 | 770 | 1.475 |
3 | 62048 | 1.460 |
1 | 50000 | 1.455 |
Price($) | Vol. | No. |
---|---|---|
1.490 | 21995 | 1 |
1.505 | 24000 | 1 |
1.510 | 13666 | 2 |
1.515 | 99798 | 1 |
1.520 | 27250 | 3 |
Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |